Guidance on pharmacovigilance procedures

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has provided comprehensive guidance for all UK Marketing Authorisation Holders (MAHs) regarding pharmacovigilance requirements following the United Kingdom's exit from the European Union. As this documentation serves as general regulatory instruction for the industry, no individual company name, specific inspection dates, or particular violations are identified; instead, the requirements apply universally to all MAHs operating within the UK. The overarching regulatory framework is defined by the UK's modifications to the European Union's Good Pharmacovigilance Practices (GVP), supplemented by the implementation of the Windsor Framework. The main issues addressed involve the complex transition of safety monitoring protocols and the distinct reporting requirements necessitated for medicinal products in Northern Ireland versus Great Britain. These regulatory expectations were detailed through a series of webinars conducted between January 2020 and September 2024. Required actions for companies include a mandatory review of the MHRA’s Windsor Framework guidance and the associated Q&A documentation to ensure their safety databases and reporting structures remain fully compliant with current laws. MAHs must actively update their pharmacovigilance systems to align with these UK-specific territorial modifications and reporting timelines. Adhering to these instructions is critical for maintaining market authorization, preventing regulatory action, and ensuring the ongoing safety monitoring of medicinal products within the newly independent regulatory landscape.